Idiopathic Pulmonary Fibrosis

Insilico Medicine’s AI-identified drug candidate, rentosertib, targeting idiopathic pulmonary fibrosis (IPF), has advanced to Phase III trials. Rentosertib, which inhibits TNIK, demonstrated significant FVC improvement in a Phase IIa trial. The drug’s discovery and development pipeline, powered by Insilico’s Pharma.AI platform, involved AI-driven target prioritization and generative molecular engineering, achieving preclinical nomination in just 18 months. This progression validates the potential of AI in revolutionizing drug discovery by accelerating timelines and originating novel therapeutic opportunities.

Trevi Therapeutics will release topline results from its Phase 2b CORAL trial of Haduvio, an investigational therapy for chronic cough in idiopathic pulmonary fibrosis (IPF). A conference call and webcast will be held on June 2nd, 2025, at 8:30 a.m. ET to discuss the findings. Haduvio targets the cough reflex arc, and initial trials show promising reduction in cough frequency. The results are highly anticipated as there is currently no approved therapy for IPF chronic cough. Further information can be found on the company’s website.